Kidney Transplant Rejection, Pediatric Kidney Disease
Conditions
Brief summary
The goal of this observational study is to compare the efficacy of two most commonly used induction therapy for the prevention of acute rejection (AR) after renal transplantation in children. The main question it aims to answer is: Is basiliximab (anti-CD25 monoclonal antibody) induction therapy effective and safe in preventing AR after kidney transplantation in children compared with anti-thymoglobulin polyclonal antibodies induction therapy? The transplant and follow-up data of participants will be retrospectively collected. Researchers will compare the rate of AR to see if basiliximab (anti-CD25 monoclonal antibody) induction therapy is a better option for certain pediatric kidney transplant recipients.
Interventions
As an induction treatment for kidney transplantation
DRUGrabbit ATG
As an induction treatment for kidney transplantation
Sponsors
Zhejiang University
First Affiliated Hospital, Sun Yat-Sen University
The First Affiliated Hospital of Zhengzhou University
Changhai Hospital
Gang Chen
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
* Receiving the kidney graft from a deceased donor * Basiliximab or rATG induction therapy was used in perioperative period
Exclusion criteria
* Recipients with pre-transplant calculated panel reactive antibodies (cPRA) \>10% * Recipients of combined liver, pancreas or heart transplantation * No induction or other induction therapy was used in perioperative period * Recieving the kidney graft from a living donor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acute rejection (AR) | From baseline, kidney transplantation to data collection completion (June 30, 2023) | The clinical diagnosis of AR is based on a significant increase in serum creatinine and the exclusion of other causes. The diagnosis of biopsy-confirmed AR is based on relevant histological changes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cytomegalovirus (CMV) viremia | From baseline, kidney transplantation to data collection completion (June 30, 2023) | The serum CMV is greater than 500 copies/ml |
| Pneumonia | From baseline, kidney transplantation to data collection completion (June 30, 2023) | Any pneumonia that showed the presence of lesion and required hospitalization |
| Renal graft survival | From baseline, kidney transplantation to data collection completion (June 30, 2023) | The estimated glomerular filtration rate (eGFR) of patient is \>15 ml/min/1.73m2 |
Countries
China
Outcome results
None listed